Cefepime-enmetazobactam for treating hospital-acquired pneumonia including ventilator-associated pneumonia

Cefepime-enmetazobactam is in clinical development for the treatment of adults with hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP). Pneumonia is a type of chest infection where tiny air sacs in lungs (alveoli) fill with fluid, making it harder to breathe. Symptoms include coughing, feeling tired, a high temperature, difficulty breathing, chest pain and loss of appetite. HAP is a type of pneumonia that occurs 48 hours or more after hospital admission and is not incubating at hospital admission. VAP is occurring in a patient within 48 hours or more after being on breathing machines in intensive care unit. HAP and VAP remain a significant cause of morbidity and mortality so there is a need to develop additional treatment options.